The risk of death among patients with Budd–Chiari syndrome was three times higher than in the general population. The most common cause was cardiovascular disease.
The mortality rate among patients with Budd–Chiari syndrome is three times higher than in the general population, a study by scientists from the University of Helsinki and Karolinska University in Stockholm showed. The results were published in the journal Clinical Gastroenterology and Hepatology.
The analysis showed that the mortality rate among patients with Budd–Chiari syndrome is 70 cases per 1000 person-years. In the control group the rate was lower – 28 cases per 1000 person-years. The adjusted risk ratio (HR) was 3.1.
The risk of death associated with liver disease was highest (RR = 47.6). Moreover, among the causes of death in patients with Budd–Chiari syndrome, liver pathologies accounted for only 10%. The most common cause was cardiovascular disease.
The prevalence of Budd–Chiari syndrome is 1 case per million people. Scientists studied the Swedish national registry and identified 478 people who were diagnosed with Budd–Chiari syndrome from 1987 to 2016. The control group included 4603 participants of similar sex and age from the general population. The average age was 58 years. Among patients with Budd–Chiari syndrome, 13% were diagnosed with liver disease.
The average follow-up period was 29 years. During this time, 243 patients from the study group (51%) and 1346 people from the control group (29%) died.
Budd–Chiari syndrome is an obstruction of the hepatic venous outflow that is detected at any level of the hepatic veins or the inferior vena cava and right atrium. May be asymptomatic or develop fulminant liver failure. Treatment includes thrombolysis, decompression through shunt placement, and long-term anticoagulants.